profit from every $100 of sales.
$0$100
Crescent Biopharma
$14.15-1.53% today
+9.0% in 1 year
1-year low $8.941-year high $26.98
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Crescent Biopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Crescent Biopharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Crescent Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2025 |
|---|---|
| 11 | |
| – | |
| -153 | |
| -150 | |
| -154 | |
| -12.81 | |
| – | |
| -1,407.5% | |
| -1,419.6% |
Balance sheet
| In millions of USD | 2025 |
|---|---|
| Total assets | 240 |
| Cash | 213 |
| Total debt | 2 |
| Total liabilities | 37 |
| 203 | |
| 10 | |
| -57.8% | |
| -75.8% |
Cash flow
| In millions of USD | 2025 |
|---|---|
| -72 | |
| 73 | |
| -144 | |
| Dividends paid | – |
| 0 | |
| 13 |
Valuation
- –
- –
- –
- 3.1×
- 54.5×
- –
- –
- -24.4%
- -26.0%
- 0.0%
Profitability
- 100.0%
- -1,407.5%
- -1,419.6%
- -1,336.8%
- -88.0%
- -114.4%
- -100.9%
- -81.4%
- -88.2%
- 1,223.2%
Growth
- +74.9%
- –
- −132.9%
- –
- −32.9%
Financial health
- -1.4×
- 0.01
- 0.8%
- -152.0×
- 13.78
- 13.78
- 0.06
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 946
Top 8%of 867
Bottom 3%of 986
What analysts expect
- Average price target
- $33.00
- Range
- $29.00 – $35.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | -0.70 | -0.85 | +17.6% |
| Feb 26, 2026 | -4.01 | -2.22 | −80.6% |
| Nov 6, 2025 | -1.27 | -1.01 | −25.7% |
| Jul 31, 2025 | -4.93 | -2.69 | −83.3% |
| May 14, 2025 | -0.04 | -0.05 | +20.0% |
| Feb 13, 2025 | -0.11 | -0.16 | +31.3% |
| Nov 13, 2024 | -0.15 | -0.11 | −36.4% |
| Aug 8, 2024 | -0.16 | -0.17 | +5.9% |
News
Crescent Energy files for proposed IPO of royalty subsidiarySeeking Alpha · Nov 2, 2026Crescent Energy rallies 10% amid broader energy rallySeeking Alpha · Oct 16, 2026Crescent Energy (CRGY) Stock Moves -1.89%: What You Should KnowYahoo Finance · Sep 22, 2026Why the Market Dipped But Crescent Energy (CRGY) Gained TodayYahoo Finance · Sep 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
42No pass
Philip Fisher
64Pass
Peter Lynch
100Pass
Joel Greenblatt
2No pass
Charlie Munger
59No pass
Terry Smith
50No pass
Questions about Crescent Biopharma
Is Crescent Biopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Crescent Biopharma AI analysis
What does Crescent Biopharma do?
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. It is in Biotechnology.
Does Crescent Biopharma pay a dividend?
No. Crescent Biopharma does not pay a dividend at the moment; in 2025 it returned $177,000 to shareholders by buying back its own shares.
Is Crescent Biopharma stock halal?
No. Crescent Biopharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 41% of its market value, at or above the 33% limit. How we check
How has Crescent Biopharma stock done over the past year?
Up 9.0% over the past twelve months, to $14.15. It traded between $8.94 and $26.98 and is 47.6% below its high.
Who are Crescent Biopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Crescent Biopharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.